Loading
Below, week by week, is what OnCo's record of Adult T-cell leukaemia/lymphoma says about the first two months: the order is typical, the timing is yours to ask about. A T-cell lymphoma caused by a virus, HTLV-1, which is usually caught in infancy through breast milk and causes the lymphoma decades later in a small minority of the people it infects. It occurs in people from south-western Japan, the Caribbean, west and central Africa, parts of South America, Iran and Romania, and it comes in four forms that are treated very differently. Sections appear only where the record has something to say. Orientation, not medical advice.
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
HTLV-1 serology belongs in the work-up of any T-cell lymphoma or leukaemia in a person who comes from, or whose parents come from, south-western Japan, the Caribbean, west or central Africa, parts of South America, Iran or Romania. Without the test the disease is reported as peripheral T-cell lymphoma not otherwise specified and treated on a pathway that does not fit it. A positive test is followed by confirmation that the virus is clonally integrated in the tumour cells, because asymptomatic infection is common in those populations and does not by itself mean lymphoma.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
The subclassification proposed by Shimoyama and adopted by the international consensus meetings divides the disease into acute, lymphoma, chronic and smouldering types, using the count of circulating tumour cells, the lactate dehydrogenase, the calcium and the sites involved. It is the first decision and it changes everything: the chronic and smouldering types without unfavourable features are watched, while the acute and lymphoma types are treated at once. The consensus report sets out prognostic factors and a set of response criteria specific to this disease, which is why trials in it are not reported like trials in other lymphomas.
Three things that belong to this disease and not to the rest of the family. Calcium, which can be very high because the tumour makes parathyroid hormone-related protein, and which may present as confusion, thirst or kidney failure before the lymphoma is recognised. Strongyloides stercoralis, because the immune suppression caused by the virus allows hyperinfection, which is fatal and is prevented by screening and treating before immunosuppressive therapy. And the central nervous system, which is commonly involved in the aggressive types and is examined by lumbar puncture.
Caused by human T-lymphotropic virus type 1, acquired in infancy through breastfeeding and causing lymphoma after a latency of decades in a small percentage of those infected. It occurs in people from south-western Japan, the Caribbean, west and central Africa, parts of South America, Romania and Iran, and it is the reason HTLV-1 serology belongs in the work-up of any T-cell lymphoma in a person from those populations. Four clinical types, and they are treated differently. Smouldering and chronic types without unfavourable features are watched, or treated with zidovudine and interferon alfa, which produces long remissions in the leukaemic types; antiviral therapy does not work in the lymphoma type. Acute and lymphoma types are treated with intensive chemotherapy. JCOG9801 randomised 118 patients with aggressive disease to six courses of VCAP-AMP-VECP or eight courses of biweekly CHOP, both with G-CSF and intrathecal prophylaxis: the complete response rate was 40 against 25 per cent and three-year overall survival 24 against 13 per cent, with more toxicity in the intensive arm (grade 4 neutropenia 98 against 83 per cent, grade 3 or 4 infection 32 against 15 per cent). VCAP-AMP-VECP is standard in Japan; outside Japan, CHOP or CHOEP with early referral for allogeneic transplant is more usual. Allogeneic stem cell transplant is the only treatment that cures a minority, and it is offered early because remissions are short. Mogamulizumab, an anti-CCR4 antibody first approved in Japan in 2012, produces responses in relapsed aggressive disease: in the updated phase 2 analysis of 26 relapsed patients, median progression-free survival was 5.2 months and median overall survival 14.4 months, and outcomes were better in patients who developed a rash of grade 2 or more, a signal that is being read as an immune effect rather than a side effect alone. Central nervous system involvement is common and intrathecal prophylaxis is given.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
Every term links to the glossary.